Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics Inc. (LCTX) is a clinical-stage biotechnology leader developing novel cell-based therapies for degenerative diseases. This dedicated news hub provides investors and stakeholders with timely updates on corporate developments, clinical research progress, and regulatory milestones.
Access authoritative information about LCTX's innovative platforms in cell replacement therapies and targeted drug delivery systems. Our curated collection features press releases covering clinical trial results, strategic partnerships, intellectual property updates, and scientific presentations.
Stay informed about advancements in treatments for retinal degeneration, spinal cord injuries, and oncology applications. All content is verified at source, ensuring reliable tracking of the company's progress in regenerative medicine. Bookmark this page for streamlined access to essential updates impacting LCTX's position in the biotech sector.
Lineage Cell Therapeutics (LCTX) presented positive results from their Phase 1/2a clinical study of OpRegen at the 2023 ARVO Annual Meeting. The study focused on patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Key findings include:
- 7.6 letter gain in visual acuity observed in Cohort 4 over 12 months.
- Long-term vision preservation noted up to 4 years in treated eyes.
- Improved retinal structures correlated with the extent of OpRegen bleb coverage.
CEO Brian Culley expressed optimism about ongoing collaborations with Genentech and Roche. The ongoing Phase 2a study has started enrolling patients, highlighting the potential of OpRegen to address unmet medical needs in this debilitating condition.
Lineage Cell Therapeutics announced that CEO Brian M. Culley will present at the 2023 American Association of Pharmaceutical Scientists National Biotechnology Conference on April 25, 2023, at 10:00 am ET. His presentation is part of the “Evolution of Cellular Therapy Symposium”, which features discussions on advancements in cellular therapies. The conference runs from April 23-26, 2023, at the Philadelphia Marriott Downtown Hotel. Lineage specializes in allogeneic cell therapies and operates on a robust cell therapy platform, with multiple product candidates in development, including therapies for age-related macular degeneration and acute spinal cord injuries.
For more details, visit www.lineagecell.com.
FAQ
What is the current stock price of Lineage Cell The (LCTX)?
What is the market cap of Lineage Cell The (LCTX)?
